Antisoma Plc expects to report Phase 3 data for ASA404, its drug for non-small cell lung cancer, by the middle of 2011. Assuming the data are positive, the company’s partner, Novartis, will file for marketing authorisations that same year. ---Subscribe to MedNous to access this article--- Company News
